Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,940 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Muscle Myopathies Clear all
Completed No phase listed Observational Accepts healthy volunteers

Lateral Neck Flexor Endurance and Hyperlaxity

NCT04770987
View directory record Official record
Conditions
Physical Endurance, Hypermobility, Joint, Muscular Weakness
Interventions
lateral neck flexor endurance test
Other
Lead sponsor
University of Hartford
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
West Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 21, 2026, 4:42 PM EDT
Terminated Phase 3 Interventional

Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia

NCT00754221
View directory record Official record
Conditions
Fibromyalgia
Interventions
[S,S]-Reboxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
101
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 21, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Powdered Tart Cherries on Recovery From Repeated Sprints

NCT06122038
View directory record Official record
Conditions
Inflammation, Oxidative Stress, Soreness, Muscle, Muscle Damage
Interventions
Tart Cherry Extract Powder, Placebo
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 21, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

NCT02002884
View directory record Official record
Conditions
Cerebral Palsy, Spasticity
Interventions
IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 21, 2026, 4:42 PM EDT
Recruiting Phase 1 Interventional

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

NCT07172971
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
SGLT-2 inhibitor, SGLT2 inhibitor
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
8 Years to 18 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

NCT02760264
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Vamorolone 0.25 mg/kg/day, Vamorolone 0.75 mg/kg/day, Vamorolone 2.0 mg/kg/day, Vamorolone 6.0 mg/kg/day
Drug
Lead sponsor
ReveraGen BioPharma, Inc.
Industry
Eligibility
4 Years to 6 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Davis, California • Gainesville, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Oct 21, 2026, 4:42 PM EDT
Terminated Phase 2 Interventional Results available

Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome

NCT00977171
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Orthostatic Hypotension, Neurally Mediated Hypotension, Neurogenic Orthostatic Hypotension
Interventions
Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 21, 2026, 4:42 PM EDT
Recruiting No phase listed Observational

Duloxetine Metabolism and Fibromyalgia

NCT06866444
View directory record Official record
Conditions
Fibromyalgia, Duloxetine
Interventions
Observational
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 4:42 PM EDT
Completed Phase 2 Interventional

Web-Based Program for Symptom Management in Fibromyalgia

NCT02515552
View directory record Official record
Conditions
Fibromyalgia
Interventions
The Fibromyalgia Wellness Project
Behavioral
Lead sponsor
Collinge and Associates, Inc.
Other
Eligibility
21 Years and older
Enrollment
883 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 21, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

NCT02573467
View directory record Official record
Conditions
Sporadic Inclusion Body Myositis
Interventions
Bimagrumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
36 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 21, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cranial Laser Reflex Technique for Hamstring Function

NCT03044106
View directory record Official record
Conditions
Hamstring Injury, Muscle Tone Increased, Muscle Pain, Muscle Weakness
Interventions
CLRT
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 21, 2026, 4:42 PM EDT
Completed Not applicable Interventional

A Computer-Based Intervention for Medically Unexplained Physical Symptoms

NCT00468013
View directory record Official record
Conditions
Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome
Interventions
Resilience Building Exercises, Journaling
Behavioral
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Oct 21, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Vitamin D to ENhance TraUma REcovery

NCT05458024
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Vitamin D 2, Vitamin D2 Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Worcester, Massachusetts • St Louis, Missouri • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 21, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Whey Protein Supplements on Markers of Exercise-induced Muscle Damage in Resistance-trained Individuals

NCT05100459
View directory record Official record
Conditions
Muscle Damage, Muscle Soreness
Interventions
Pasture-raised whey protein, Conventional whey protein, Placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 21, 2026, 4:42 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT05747924
View directory record Official record
Conditions
FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH
Interventions
AOC 1020, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 21, 2026, 4:42 PM EDT
Completed Phase 2 Interventional

Ibuprofen Plus Acetaminophen Versus Oxycodone Alone After Hand Surgery

NCT03111186
View directory record Official record
Conditions
Carpal Tunnel Syndrome, Dupuytren Contracture, Trigger Digit, Ganglion Cysts, De Quervain Disease
Interventions
Oxycodone Hcl 5Mg, Ibuprofen 400 mg, Acetaminophen 650 mg
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 21, 2026, 4:42 PM EDT
Terminated Phase 1 Interventional

Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States

NCT06747273
View directory record Official record
Conditions
Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type 2D/R3
Interventions
SRP-9004
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Columbus, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 21, 2026, 4:42 PM EDT
Recruiting Not applicable Interventional

Operant Conditioning of Spinal Reflexes Training System--Reflex Operant Down Conditioning

NCT05094362
View directory record Official record
Conditions
Spinal Cord Injuries, Neurological Injury, Paralysis, Spasticity, Muscle
Interventions
Spinal Reflex Operant Down Conditioning
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 21, 2026, 4:42 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Pregabalin in Fibromyalgia

NCT00151489
View directory record Official record
Conditions
Fibromyalgia
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
109
States / cities
Anniston, Alabama • Birmingham, Alabama • Calera, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 21, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

NCT01643850
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
Interventions
MCS110, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 21, 2026, 4:42 PM EDT
Recruiting Not applicable Interventional

Auricular Neuromodulation in Veterans With Fibromyalgia

NCT06415591
View directory record Official record
Conditions
Fibromyalgia
Interventions
Percutaneous electrical nerve field stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 4:42 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TenoMiR in Lateral Epicondylitis

NCT06192927
View directory record Official record
Conditions
Tennis Elbow
Interventions
TenoMiR, 0.9% Sodium Chloride Injection
Drug
Lead sponsor
Causeway Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Redwood City, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 21, 2026, 4:42 PM EDT
Withdrawn Phase 1 Interventional

Comparison of Distraction Methods for Pain Relief of Trigger Finger Injection

NCT03445780
View directory record Official record
Conditions
Trigger Finger
Interventions
Ethyl chloride spray, Pinching, No Site of Procedure
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 21, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Pain Associated With Fibromyalgia

NCT02187159
View directory record Official record
Conditions
Pain Associated With Fibromyalgia
Interventions
DS-5565, Pregabalin, Placebo tablet, Placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 21, 2026, 4:42 PM EDT